lidocaine has been researched along with Auricular Fibrillation in 170 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 9.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "Population pharmacokinetics (PK) of a sodium channel-blocking antiarrhythmic, pilsicainide, was studied using the nonlinear mixed-effects modeling technique in 91 patients with cardiac arrhythmias (80 suspected Brugada syndrome [BrS] and 11 with atrial fibrillation) who received an intravenous infusion of 10 mg of the drug." | 9.12 | Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. ( Echizen, H; Kishi, R; Kobayashi, S; Masuhara, K; Matsumoto, N; Mihara, K; Miyake, F; Nakazawa, K; Ogawa, R; Takagi, A; Takahashi, H, 2006) |
| "The present study was conducted to determine the antiarrhythmic efficacy and safety of oral pilsicainide, a class Ic antiarrhythmic drug, in patients with persistent atrial fibrillation (AF)." | 9.12 | Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II. ( Atarashi, H; Fukunami, M; Inoue, H; Kumagai, K; Okishige, K, 2006) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 9.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| " low-dose flecainide followed by oral pilsicainide might be a promising strategy for the outpatient treatment of paroxysmal atrial fibrillation." | 9.10 | Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation. ( Kubota, I; Nagai, S; Takeishi, Y, 2003) |
| "A single oral dose of pilsicainide (PLS) is effective in terminating acute-onset atrial fibrillation (AF)." | 9.09 | Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. ( Abe, H; Hiraki, T; Ikeda, H; Imaizumi, T; Kumagai, K; Nakashima, H; Nakashima, Y; Oginosawa, Y; Saku, K, 2000) |
| "In this population of patients referred for elective cardioversion of atrial fibrillation, high-dose bolus lidocaine was ineffective in converting patients to sinus rhythm." | 9.09 | High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial. ( Bardy, GH; Marrouche, NF; Reddy, RK; Wittkowsky, AK, 2000) |
| "The efficacy and safety of a single oral dose of 150-mg pilsicainide, a new class Ic antiarrhythmic drug, in converting recent-onset atrial fibrillation to sinus rhythm were evaluated in 75 patients (51 men, 24 women; age 23 to 74 years)." | 9.08 | Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators. ( Atarashi, H; Hayakawa, H; Hiejima, K; Inoue, H, 1996) |
| "A single oral dose of pilsicainide, a Class Ic antiarrhythmic drug, is a widely used and highly effective therapy for termination of recent onset atrial fibrillation." | 8.80 | Ventricular pacing failure after a single oral dose of pilsicainide in a patient with a permanent pacemaker and paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "Arrhythmias associated with lidocaine should be considered when treating dogs with supraventricular tachyarrhythmia." | 8.12 | Rhythm disturbances associated with lidocaine administration in four dogs with supraventricular tachyarrhythmias. ( Connolly, DJ; Luis Fuentes, V; Porteiro Vázquez, DM; Seo, J; Spalla, I; Tinson, E, 2022) |
| "Background This study assessed the effect of blockading neural transmission in the ganglionated plexi by injecting lidocaine into fat pads in the vagal nerve stimulation canine model and patients with persistent atrial fibrillation ( AF )." | 7.91 | Effect of Lidocaine Injection of Ganglionated Plexi in a Canine Model and Patients With Persistent and Long-Standing Persistent Atrial Fibrillation. ( Khrestian, A; Khrestian, CM; Lee, S; Markowitz, A; Sahadevan, J; Waldo, AL, 2019) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 7.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "Pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects were simultaneously assessed using chronic atrioventricular block dogs." | 7.75 | Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs. ( Iwasaki, H; Nagai, T; Nakamura, Y; Satoh, Y; Shinkai, N; Sugiyama, A; Takahara, A, 2009) |
| "It has been shown that pilsicainide terminates atrial fibrillation (AF) by pharmacologic pulmonary vein (PV) isolation." | 7.74 | Mechanisms of the preventive effect of pilsicainide on atrial fibrillation originating from the pulmonary vein. ( Hamazaki, M; Hirose, M; Ohkubo, Y; Sekido, T; Takano, M; Yamada, M, 2007) |
| "The factors affecting successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride are unclear." | 7.72 | [Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| "A 56-year-old man with Brugada syndrome presented with ventricular fibrillation induced by administration of pilsicainide." | 7.72 | [Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: a case report]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 7.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "This study evaluated the efficacy of long-term pilsicainide therapy to maintain sinus rhythm in patients with paroxysmal atrial fibrillation in terms of the time of onset." | 7.71 | [Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset]. ( Kimura, M; Komatsu, T; Nakamura, S; Okumura, K; Owada, S; Tomita, H; Yomogida, K, 2001) |
| "The effects of pilsicainide on vagally induced atrial fibrillation and on electrophysiological parameters were compared with those of propafenone in alpha-chloralose-anesthetized dogs." | 7.70 | Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. ( Iwasa, A; Matsunaga, T; Okumura, K; Tabuchi, T; Tayama, S; Tsuchiya, T; Tsunoda, R; Yasue, H, 1998) |
| "The antifibrillatory effect of pilsicainide, a sodium channel blocker with slow recovery kinetics, was investigated in a canine model of atrial fibrillation." | 7.70 | Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Sueyoshi, K; Takatsuki, S, 1998) |
| "An 81-year-old woman developed pilsicainide intoxication associated with dehydration." | 7.70 | Pilsicainide intoxication in a patient with dehydration. ( Matsuo, S; Ozeki, S; Utsunomiya, T; Yano, K, 1999) |
| "The purposes of this study were to measure the atrial refractory period and the conduction velocity (CV) during atrial fibrillation (AF) and to explore the antiarrhythmic mechanism of a sodium channel blocker, pilsicainide, during AF." | 7.70 | Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Takatsuki, S; Takeshita, A, 2000) |
| "A single oral dose of pilsicainide, a class 1c antiarrhythmic drug, is effective in terminating acute-onset atrial fibrillation (AF), but its effect on pacing thresholds in pacemaker patients is unknown." | 7.70 | Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "This study investigated the effects of a particular type of sodium channel blocker, pilsicainide, on spiral waves, which are a possible mechanism of atrial fibrillation, by using numerical simulation." | 7.70 | Effect of pilsicainide, a pure sodium channel blocker, on spiral waves during atrial fibrillation: theoretical analysis by numerical simulation. ( Ashihara, T; Nakazawa, K; Namba, T; Ohe, T, 1999) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 7.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "To inventigate the electrophysiologic effects of pilsicainide hydrochloride on atrial fibrillation, we compared atrial fibrillation threshold (AFT), right atrial effective refractory period (RAERP), and inter-atrial conduction time (Inter-ACT) before and after the administration of pilsicainide in 12 patients with lone paroxysmal atrial fibrillation." | 7.68 | [Effect of pilsicainide hydrochloride on atrial fibrillation threshold]. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Shirayama, T; Yamahara, Y, 1993) |
| "Clinical experience has shown that the antiarrhythmic effect of lidocaine on atrial arrhythmias, and specifically for the conversion of atrial fibrillation to normal sinus rhythm, is minimal." | 7.68 | Parasympathetically modulated antiarrhythmic action of lidocaine in atrial fibrillation. ( Akselrod, S; Borow, KM; David, D; Lang, RM; Mor-Avi, V; Neumann, A, 1990) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 7.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "This report describes a case of Wolff-Parkinson-White syndrome with atrial fibrillation in which the ventricular complexes conducted over the accessory pathway have promptly disappeared with the use of intravenously administered lidocaine." | 7.66 | [Lidocaine administration in a patient with Wolff-Parkinson-White syndrome and atrial fibrillation (author's transl)]. ( Marzaloni, M; Rossi, F; Rusconi, L; Sermasi, S, 1979) |
| "To assess atrial and ventricular rate changes after lidocaine injection, 18 atrial flutter patients and 35 atrial fibrillation patients were given intravenous lidocaine, mean dose 100 mg." | 7.66 | Lidocaine-induced cardiac rate changes in atrial fibrillation and atrial flutter. ( Aronow, WS; Danahy, DT, 1978) |
| "The effect of lidocaine on the atrial fibrillation threshold (AFT) and the ventricular fibrillation threshold (VFT) was studied in anesthetized dogs." | 7.65 | Effect of lidocaine on the atrial fibrillation threshold. ( Gerber, NH; Goodking, MJ; Gotzoyannis, S; Kostis, JB; Kuo, PT, 1977) |
| "Pilsicainide is a newly synthesized antiarrhythmic agent with class Ic properties." | 6.69 | Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. ( Aonuma, K; Azegami, K; Igawa, M; Nishizaki, M; Okishige, K; Yamawaki, N, 2000) |
| "Pilsicainide is a class IC antiarrhythmic drug, which has a pure sodium channel blocking action with slow recovery pharmacokinetics." | 6.43 | Pilsicainide for atrial fibrillation. ( Kumagai, K; Matsumoto, N; Nakashima, H; Noguchi, H; Ogawa, M; Saku, K; Tojo, H; Yasuda, T, 2006) |
| "Ranolazine was more effective than lidocaine in terminating persistent AF and in preventing the induction of AF." | 5.34 | Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Zygmunt, AC, 2007) |
| "It has been reported that bepridil is as good as amiodarone in converting persistent atrial fibrillation (AF) to sinus rhythm (SR)." | 5.13 | Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm. ( Aoyama, H; Enomoto, M; Hirayama, A; Imai, S; Kushiro, T; Saito, F; Takase, H; Yagi, H; Yamaji, S; Yokoyama, K, 2008) |
| "Population pharmacokinetics (PK) of a sodium channel-blocking antiarrhythmic, pilsicainide, was studied using the nonlinear mixed-effects modeling technique in 91 patients with cardiac arrhythmias (80 suspected Brugada syndrome [BrS] and 11 with atrial fibrillation) who received an intravenous infusion of 10 mg of the drug." | 5.12 | Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias. ( Echizen, H; Kishi, R; Kobayashi, S; Masuhara, K; Matsumoto, N; Mihara, K; Miyake, F; Nakazawa, K; Ogawa, R; Takagi, A; Takahashi, H, 2006) |
| "The present study was conducted to determine the antiarrhythmic efficacy and safety of oral pilsicainide, a class Ic antiarrhythmic drug, in patients with persistent atrial fibrillation (AF)." | 5.12 | Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II. ( Atarashi, H; Fukunami, M; Inoue, H; Kumagai, K; Okishige, K, 2006) |
| " low-dose flecainide followed by oral pilsicainide might be a promising strategy for the outpatient treatment of paroxysmal atrial fibrillation." | 5.10 | Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation. ( Kubota, I; Nagai, S; Takeishi, Y, 2003) |
| "[corrected] Bepridil, a multiple ion-channel blocker, has been reported to prevent paroxysmal atrial fibrillation (PAF)." | 5.10 | Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "In this population of patients referred for elective cardioversion of atrial fibrillation, high-dose bolus lidocaine was ineffective in converting patients to sinus rhythm." | 5.09 | High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial. ( Bardy, GH; Marrouche, NF; Reddy, RK; Wittkowsky, AK, 2000) |
| "A single oral dose of pilsicainide (PLS) is effective in terminating acute-onset atrial fibrillation (AF)." | 5.09 | Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial. ( Abe, H; Hiraki, T; Ikeda, H; Imaizumi, T; Kumagai, K; Nakashima, H; Nakashima, Y; Oginosawa, Y; Saku, K, 2000) |
| "The efficacy and safety of a single oral dose of 150-mg pilsicainide, a new class Ic antiarrhythmic drug, in converting recent-onset atrial fibrillation to sinus rhythm were evaluated in 75 patients (51 men, 24 women; age 23 to 74 years)." | 5.08 | Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators. ( Atarashi, H; Hayakawa, H; Hiejima, K; Inoue, H, 1996) |
| "A single oral dose of pilsicainide, a Class Ic antiarrhythmic drug, is a widely used and highly effective therapy for termination of recent onset atrial fibrillation." | 4.80 | Ventricular pacing failure after a single oral dose of pilsicainide in a patient with a permanent pacemaker and paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "Arrhythmias associated with lidocaine should be considered when treating dogs with supraventricular tachyarrhythmia." | 4.12 | Rhythm disturbances associated with lidocaine administration in four dogs with supraventricular tachyarrhythmias. ( Connolly, DJ; Luis Fuentes, V; Porteiro Vázquez, DM; Seo, J; Spalla, I; Tinson, E, 2022) |
| "Background This study assessed the effect of blockading neural transmission in the ganglionated plexi by injecting lidocaine into fat pads in the vagal nerve stimulation canine model and patients with persistent atrial fibrillation ( AF )." | 3.91 | Effect of Lidocaine Injection of Ganglionated Plexi in a Canine Model and Patients With Persistent and Long-Standing Persistent Atrial Fibrillation. ( Khrestian, A; Khrestian, CM; Lee, S; Markowitz, A; Sahadevan, J; Waldo, AL, 2019) |
| "Administration of pilsicainide, a class IC antiarrhythmic agent, caused Brugada- type ST elevation in a 66-year-old Japanese male who presented with paroxysmal atrial fibrillation (PAF), type I atrial flutter and inducible ventricular fibrillation (VF) during electrophysiological study." | 3.83 | A Novel SCN5A Mutation Associated with Drug Induced Brugada Type ECG. ( Ai, T; Horie, M; Itoh, H; Makiyama, T; Shimizu, A; Turker, I; Ueyama, T; Vatta, M, 2016) |
| " The sheep were prophylactically treated with amiodarone plus lidocaine before ligation of the four to six coronary artery branches supplying the apex of the heart (arrhythmia prevention [AP] group, n = 45) and with epinephrine (shock prevention [SP] group, n = 49), respectively." | 3.79 | Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction. ( Griffith, BP; Li, T; Sanchez, PG; Watkins, AC; Wei, X; Wu, ZJ, 2013) |
| "Pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects were simultaneously assessed using chronic atrioventricular block dogs." | 3.75 | Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs. ( Iwasaki, H; Nagai, T; Nakamura, Y; Satoh, Y; Shinkai, N; Sugiyama, A; Takahara, A, 2009) |
| "It has been shown that pilsicainide terminates atrial fibrillation (AF) by pharmacologic pulmonary vein (PV) isolation." | 3.74 | Mechanisms of the preventive effect of pilsicainide on atrial fibrillation originating from the pulmonary vein. ( Hamazaki, M; Hirose, M; Ohkubo, Y; Sekido, T; Takano, M; Yamada, M, 2007) |
| "Disopyramide is thought to have an advantageous effect for atrial fibrillation (AF) associated with vagal activity because of its anticholinergic effect." | 3.73 | Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation. ( Aizawa, Y; Chinushi, M; Hirono, T; Komura, S; Sugiura, H, 2005) |
| "We treated an 88-year-old man with aortic valvular stenosis/insufficiency and paroxysmal atrial fibrillation, who developed ventricular tachycardia due to pilsicainide toxicity." | 3.72 | A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings. ( Funada, A; Horita, Y; Kaku, B; Kanaya, H; Kitajima, S; Matsumura, M; Satoh, T; Uno, Y; Yamazaki, T, 2004) |
| "The factors affecting successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride are unclear." | 3.72 | [Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| "This study aimed to assess the effects of pilsicainide, a pure sodium channel blocker, on electrophysiological action and wavefront dynamics during atrial fibrillation (AF)." | 3.72 | Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria. ( Ashihara, T; Hirai, H; Ikeda, T; Kawase, A; Kubota, T; Nakazawa, K; Namba, T; Sugi, K, 2003) |
| "Bepridil, a multi-ion channel blocker, is effective for some types of cardiac arrhythmias, and so its effect on the paroxysmal atrial fibrillation (PAF) was evaluated in the present study, comparing it with class Ic antiarrhythmic drugs." | 3.72 | Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings. ( Hara, H; Ikeda-Murakami, K; Inuo, K; Izumi, T; Kojima, J; Niwano, S; Saito, J; Yoshida, T, 2003) |
| "A 56-year-old man with Brugada syndrome presented with ventricular fibrillation induced by administration of pilsicainide." | 3.72 | [Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: a case report]. ( Ebina, T; Ishikawa, T; Kimura, K; Kobayashi, T; Matsumoto, K; Matsushita, K; Mochida, Y; Nakagawa, T; Nakazawa, I; Ohkusu, Y; Sumita, S; Uchino, K; Umemura, S; Yamakawa, Y, 2003) |
| " Pilsicainide (four patients) or flecainide (one patient) were administered orally for the treatment of symptomatic paroxysmal atrial fibrillation or premature atrial contractions." | 3.71 | ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs. ( Kawano, Y; Mineda, Y; Nakata, Y; Nakazato, K; Nakazato, Y; Sekita, G; Sumiyoshi, M; Tokano, T; Yamashita, H; Yasuda, M, 2001) |
| " During hospitalization, atrial fibrillation developed, and oral pilsicainide was administered." | 3.71 | Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina. ( Aizawa, Y; Chinushi, M; Chinushi, Y; Toida, T, 2002) |
| "This study evaluated the efficacy of long-term pilsicainide therapy to maintain sinus rhythm in patients with paroxysmal atrial fibrillation in terms of the time of onset." | 3.71 | [Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset]. ( Kimura, M; Komatsu, T; Nakamura, S; Okumura, K; Owada, S; Tomita, H; Yomogida, K, 2001) |
| "The antifibrillatory effect of pilsicainide, a sodium channel blocker with slow recovery kinetics, was investigated in a canine model of atrial fibrillation." | 3.70 | Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Sueyoshi, K; Takatsuki, S, 1998) |
| "An 81-year-old woman developed pilsicainide intoxication associated with dehydration." | 3.70 | Pilsicainide intoxication in a patient with dehydration. ( Matsuo, S; Ozeki, S; Utsunomiya, T; Yano, K, 1999) |
| "This study investigated the effects of a particular type of sodium channel blocker, pilsicainide, on spiral waves, which are a possible mechanism of atrial fibrillation, by using numerical simulation." | 3.70 | Effect of pilsicainide, a pure sodium channel blocker, on spiral waves during atrial fibrillation: theoretical analysis by numerical simulation. ( Ashihara, T; Nakazawa, K; Namba, T; Ohe, T, 1999) |
| "The purposes of this study were to measure the atrial refractory period and the conduction velocity (CV) during atrial fibrillation (AF) and to explore the antiarrhythmic mechanism of a sodium channel blocker, pilsicainide, during AF." | 3.70 | Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide. ( Kanki, H; Mitamura, H; Ogawa, S; Sato, T; Shinagawa, K; Takatsuki, S; Takeshita, A, 2000) |
| "A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later." | 3.70 | A case of sinus pause due to the proarrhythmia of pilsicainide. ( Abe, T; Fuse, K; Murooka, H; Saigawa, T; Susa, R; Toeda, T; Yamaguchi, Y, 2000) |
| "A single oral dose of pilsicainide, a class 1c antiarrhythmic drug, is effective in terminating acute-onset atrial fibrillation (AF), but its effect on pacing thresholds in pacemaker patients is unknown." | 3.70 | Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation. ( Abe, H; Kohshi, K; Nagatomo, T; Nakashima, Y; Numata, T, 2000) |
| "Increased dispersion of signal-averaged P wave duration would play an important role in generating paroxysmal atrial fibrillation and would be useful in the prediction of drug efficacy to evaluate the change in dispersion by a single administration of pilsicainide." | 3.70 | Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation. ( Asano, Y; Fukunami, M; Hoki, N; Hori, M; Kumagai, K; Ogita, H; Sanada, S; Shimonagata, T; Yamada, T, 1999) |
| "Effects of class Ic drug pilsicainide and class III drug MS-551 were determined in the canine model of atrial fibrillation (AF) induced under vagal stimulation." | 3.70 | Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart. ( Fujiki, A; Hayashi, H; Inoue, H; Tani, M; Usui, M, 1998) |
| "The effects of pilsicainide on vagally induced atrial fibrillation and on electrophysiological parameters were compared with those of propafenone in alpha-chloralose-anesthetized dogs." | 3.70 | Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity. ( Iwasa, A; Matsunaga, T; Okumura, K; Tabuchi, T; Tayama, S; Tsuchiya, T; Tsunoda, R; Yasue, H, 1998) |
| "The effects of E-4031, a new class III antiarrhythmic agent, on atrial fibrillation threshold (AFT), atrial effective refractory period (ERP), and interatrial conduction time (ACT) were investigated in Langendorff-perfused guinea pig hearts; the results were then compared with those of the class I agents disopyramide, procainamide, lidocaine, and flecainide." | 3.69 | Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Sakai, R; Shirayama, T, 1994) |
| "The effects of pilsicainide, a new class Ic antiarrhythmic agent, on the atrial fibrillation threshold (AFT), the atrial effective refractory period (ERP), and the interatrial conduction time (ACT) in Langendorff-perfused guinea pig hearts were investigated." | 3.68 | Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Yamahara, Y, 1993) |
| "To inventigate the electrophysiologic effects of pilsicainide hydrochloride on atrial fibrillation, we compared atrial fibrillation threshold (AFT), right atrial effective refractory period (RAERP), and inter-atrial conduction time (Inter-ACT) before and after the administration of pilsicainide in 12 patients with lone paroxysmal atrial fibrillation." | 3.68 | [Effect of pilsicainide hydrochloride on atrial fibrillation threshold]. ( Asayama, J; Inoue, D; Inoue, M; Ishibashi, K; Nakagawa, M; Omori, I; Sakai, R; Shirayama, T; Yamahara, Y, 1993) |
| " Three bipolar epicardial electrodes recorded left atrial and left and right ventricular depolarizations simultaneously during normal sinus rhythm (NSR) (mean of 5 beats in 11/11 dogs), ST produced by phlebotomy (50 beats in 10 episodes in 6/11) or isoproterenol infusion (105 beats in 21 episodes in 10/11), sinus bradycardia (SB) produced by vagal stimulation (140 beats in 29 episodes in 10/11), and during atrial flutter (AFL) (15 beats in 3 episodes in 3/11) and atrial fibrillation (AF) (152 beats in 31 episodes in 9/11) induced by programmed electrical stimulation." | 3.68 | Differentiation of sinus rhythms from supraventricular tachydysrhythmias by activation sequence and timing. ( Furman, S; Mercando, AD; Singer, LP; Walsh, CA, 1990) |
| "Clinical experience has shown that the antiarrhythmic effect of lidocaine on atrial arrhythmias, and specifically for the conversion of atrial fibrillation to normal sinus rhythm, is minimal." | 3.68 | Parasympathetically modulated antiarrhythmic action of lidocaine in atrial fibrillation. ( Akselrod, S; Borow, KM; David, D; Lang, RM; Mor-Avi, V; Neumann, A, 1990) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 3.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "The antiarrhythmic effects of diltiazem (DL), a slow channel inhibitor, were evaluated in the presence of epinephrine-halothane-induced arrhythmias in dogs, of premature ventricular contractions (PVCs) during anesthesia in patients (n = 10), and of tachyarrhythmias with associated atrial fibrillation (AF) during anesthesia in patients (n = 9)." | 3.67 | Antiarrhythmic effect of diltiazem during halothane anesthesia in dogs and in humans. ( Amaha, K; Iwatsuki, N; Katoh, M; Ono, K, 1985) |
| " The prevention of ventricular arrhythmias with prophylactic lidocaine is advocated for patients with suspected acute myocardial infarction." | 3.66 | Therapeutic considerations in the treatment of common cardiac arrhythmias. ( Hart, NJ, 1981) |
| "To assess atrial and ventricular rate changes after lidocaine injection, 18 atrial flutter patients and 35 atrial fibrillation patients were given intravenous lidocaine, mean dose 100 mg." | 3.66 | Lidocaine-induced cardiac rate changes in atrial fibrillation and atrial flutter. ( Aronow, WS; Danahy, DT, 1978) |
| "This report describes a case of Wolff-Parkinson-White syndrome with atrial fibrillation in which the ventricular complexes conducted over the accessory pathway have promptly disappeared with the use of intravenously administered lidocaine." | 3.66 | [Lidocaine administration in a patient with Wolff-Parkinson-White syndrome and atrial fibrillation (author's transl)]. ( Marzaloni, M; Rossi, F; Rusconi, L; Sermasi, S, 1979) |
| "The effect of lidocaine on the atrial fibrillation threshold (AFT) and the ventricular fibrillation threshold (VFT) was studied in anesthetized dogs." | 3.65 | Effect of lidocaine on the atrial fibrillation threshold. ( Gerber, NH; Goodking, MJ; Gotzoyannis, S; Kostis, JB; Kuo, PT, 1977) |
| "Lidocaine was 1:1 randomly infused to the right or left ganglion." | 2.82 | Acute effects of unilateral temporary stellate ganglion block on human atrial electrophysiological properties and atrial fibrillation inducibility. ( Arvaniti, C; Batistaki, C; Deftereos, S; Flevari, P; Giannopoulos, G; Katsaras, D; Kossyvakis, C; Kostopanagiotou, G; Leftheriotis, D; Lekakis, J, 2016) |
| "Pilsicainide and bepridil were effective in 19 and 20 patients, respectively." | 2.74 | Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG. ( Fujiki, A; Fukaya, H; Hatakeyama, Y; Izumi, T; Kiryu, M; Kurokawa, S; Niwano, H; Niwano, S; Sasaki, T, 2009) |
| "Pilsicainide is a newly synthesized antiarrhythmic agent with class Ic properties." | 2.69 | Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study. ( Aonuma, K; Azegami, K; Igawa, M; Nishizaki, M; Okishige, K; Yamawaki, N, 2000) |
| "The mean number of runs of ventricular tachycardia per patient was 0." | 2.67 | Lidocaine prophylaxis in coronary revascularization patients: a randomized, prospective trial. ( Goldberger, AL; Johnson, RG; Schwartz, M; Sirois, C; Thurer, RL; Weintraub, RM, 1993) |
| "Pilsicainide is a class IC antiarrhythmic drug, which has a pure sodium channel blocking action with slow recovery pharmacokinetics." | 2.43 | Pilsicainide for atrial fibrillation. ( Kumagai, K; Matsumoto, N; Nakashima, H; Noguchi, H; Ogawa, M; Saku, K; Tojo, H; Yasuda, T, 2006) |
| "Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular tachyarrhythmias, and seems to be superior to other antiarrhythmic agents." | 2.42 | Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003) |
| "Lidocaine action was modeled with the Hondeghem-Katzung modulated-receptor theory and maximum affinity for activated Na(+) channels." | 1.35 | Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. ( Comtois, P; Munoz, M; Nattel, S; Sakabe, M; Shiroshita-Takeshita, A; Texier, A; Vigmond, EJ, 2008) |
| "Ranolazine was more effective than lidocaine in terminating persistent AF and in preventing the induction of AF." | 1.34 | Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. ( Antzelevitch, C; Belardinelli, L; Burashnikov, A; Di Diego, JM; Zygmunt, AC, 2007) |
| "Patient 1 had frequent episodes of paroxysmal atrial fibrillation resistant to Class IA drugs." | 1.30 | ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. ( Fujiki, A; Hayashi, H; Inoue, H; Mizumaki, K; Nagasawa, H; Usui, M, 1999) |
| " R56865 was given before ischemia and with the onset of reperfusion, applying different dosing schedules, including an initial loading dose." | 1.29 | R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion. ( Guttmann, I; Mozes, A; Scheufler, E; Wilffert, B, 1995) |
| "Flecainide-induced VF was antagonized by glibenclamide." | 1.29 | Antifibrillatory and profibrillatory actions of selected class I antiarrhythmic agents. ( Chi, L; Fagbemi, SO; Lucchesi, BR, 1993) |
| "Cardiac arrhythmias and conduction disturbances are commonly observed in patients with myocardial infarction." | 1.27 | Treatment of cardiac arrhythmias in patients with acute myocardial infarction. ( Scheinman, MM, 1983) |
| "In 6 patients with congestive heart failure, P-C PG was reversed from -2." | 1.27 | Pressure gradient and blood flow in human arm veins--a proposed explanation of the pumping mechanism. ( Fujiwara, H; Soma, T; Watanabe, R, 1984) |
| "Multiple cardiac arrhythmias consisting of multifocal, or unifocal, multiform ventricular ectopic beats, bidirectional tachycardia, complete heart block, accelerated junctional rhythm with exit block, nonparoxysmal junctional tachycardia, atrial fibrillation, atrial tachycardia with block, and multifocal tachycardia were observed." | 1.26 | Digitalis-induced cardiac arrhythmias. ( Chia, BL, 1981) |
| "of lidocaine were investigated in 39 patients with impulse formation and conduction defects by means of His-bundle recording and were correlated with plasma lidocaine levels." | 1.25 | Effects of lidocaine on impulse formation and conduction defects in man. ( Dunning, AJ; Roos, JC, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (47.06) | 18.7374 |
| 1990's | 22 (12.94) | 18.2507 |
| 2000's | 46 (27.06) | 29.6817 |
| 2010's | 19 (11.18) | 24.3611 |
| 2020's | 3 (1.76) | 2.80 |
| Authors | Studies |
|---|---|
| McMaster, PD | 2 |
| Byrnes, EW | 2 |
| Feldman, HS | 2 |
| Takman, BH | 2 |
| Tenthorey, PA | 2 |
| DiRubio, RL | 1 |
| Plouvier, B | 1 |
| Beatch, GN | 1 |
| Jung, GL | 1 |
| Zolotoy, A | 1 |
| Sheng, T | 1 |
| Clohs, L | 1 |
| Barrett, TD | 1 |
| Fedida, D | 1 |
| Wang, WQ | 1 |
| Zhu, JJ | 1 |
| Liu, Y | 1 |
| Abraham, S | 1 |
| Lynn, L | 1 |
| Dong, Y | 1 |
| Wall, RA | 1 |
| Walker, MJ | 1 |
| Seo, J | 1 |
| Spalla, I | 1 |
| Porteiro Vázquez, DM | 1 |
| Luis Fuentes, V | 1 |
| Tinson, E | 1 |
| Connolly, DJ | 1 |
| Irie, M | 1 |
| Hiiro, H | 1 |
| Hamaguchi, S | 1 |
| Namekata, I | 1 |
| Tanaka, H | 1 |
| Asano, M | 1 |
| Hayakawa, T | 1 |
| Kato, Y | 1 |
| Kawada, K | 1 |
| Goto, S | 1 |
| Branch, J | 1 |
| Shimizu, H | 1 |
| Thorn, CL | 1 |
| Vezina-Audette, R | 1 |
| Gelzer, AR | 1 |
| Akkuş, M | 1 |
| Öner, E | 1 |
| Lee, S | 1 |
| Khrestian, A | 1 |
| Waldo, AL | 1 |
| Khrestian, CM | 1 |
| Markowitz, A | 1 |
| Sahadevan, J | 1 |
| Hanna, P | 1 |
| Zhu, C | 1 |
| Rajendran, PS | 1 |
| Shivkumar, K | 1 |
| Li, T | 1 |
| Wei, X | 1 |
| Watkins, AC | 1 |
| Sanchez, PG | 1 |
| Wu, ZJ | 1 |
| Griffith, BP | 1 |
| Takahara, A | 3 |
| Suzuki, S | 1 |
| Hagiwara, M | 1 |
| Nozaki, S | 1 |
| Sugiyama, A | 3 |
| Nakamura, K | 1 |
| Fukami, N | 1 |
| Yagishita, A | 1 |
| Yamauchi, Y | 1 |
| Obayashi, T | 1 |
| Hirao, K | 2 |
| Burashnikov, A | 4 |
| Belardinelli, L | 3 |
| Antzelevitch, C | 4 |
| Highsmith, JT | 1 |
| Koubek, V | 1 |
| Monheit, GD | 1 |
| Leftheriotis, D | 1 |
| Flevari, P | 1 |
| Kossyvakis, C | 1 |
| Katsaras, D | 1 |
| Batistaki, C | 1 |
| Arvaniti, C | 1 |
| Giannopoulos, G | 1 |
| Deftereos, S | 1 |
| Kostopanagiotou, G | 1 |
| Lekakis, J | 1 |
| Turker, I | 1 |
| Makiyama, T | 1 |
| Vatta, M | 1 |
| Itoh, H | 1 |
| Ueyama, T | 1 |
| Shimizu, A | 1 |
| Ai, T | 1 |
| Horie, M | 1 |
| Ohgoshi, Y | 1 |
| Takeda, M | 1 |
| Miura, M | 1 |
| Kori, S | 1 |
| Matsukawa, M | 1 |
| Comtois, P | 1 |
| Sakabe, M | 1 |
| Vigmond, EJ | 1 |
| Munoz, M | 1 |
| Texier, A | 1 |
| Shiroshita-Takeshita, A | 1 |
| Nattel, S | 2 |
| Komatsu, T | 3 |
| Tachibana, H | 2 |
| Sato, Y | 2 |
| Ozawa, M | 1 |
| Ohshima, K | 1 |
| Orii, M | 1 |
| Kunigida, F | 1 |
| Nakamura, M | 2 |
| Horiuchi, D | 2 |
| Iwasa, A | 2 |
| Sasaki, K | 1 |
| Owada, S | 2 |
| Kimura, M | 2 |
| Sasaki, S | 1 |
| Okumura, K | 4 |
| Niwano, S | 5 |
| Sasaki, T | 1 |
| Kurokawa, S | 1 |
| Kiryu, M | 1 |
| Fukaya, H | 1 |
| Hatakeyama, Y | 1 |
| Niwano, H | 1 |
| Fujiki, A | 3 |
| Izumi, T | 5 |
| Iwasaki, H | 1 |
| Nakamura, Y | 2 |
| Satoh, Y | 1 |
| Nagai, T | 1 |
| Shinkai, N | 1 |
| Nof, E | 1 |
| Lazzara, R | 1 |
| Indik, JH | 1 |
| Landy, C | 1 |
| Schaeffer, E | 1 |
| Raynaud, L | 1 |
| Favier, JC | 1 |
| Plancade, D | 1 |
| Watanabe, I | 1 |
| Okumura, Y | 1 |
| Ohkubo, K | 1 |
| Nagashima, K | 1 |
| Sonoda, K | 1 |
| Mano, H | 1 |
| Kofune, M | 1 |
| Hirayama, A | 2 |
| Stuart-Smith, K | 1 |
| Shirayama, T | 3 |
| Shiraishi, H | 1 |
| Yoshida, S | 1 |
| Matoba, Y | 1 |
| Imai, H | 1 |
| Nakagawa, M | 4 |
| Yoshida, T | 2 |
| Inuo, K | 3 |
| Saito, J | 3 |
| Kojima, J | 3 |
| Ikeda-Murakami, K | 2 |
| Hara, H | 2 |
| Kawase, A | 1 |
| Ikeda, T | 1 |
| Nakazawa, K | 3 |
| Ashihara, T | 2 |
| Namba, T | 2 |
| Kubota, T | 1 |
| Sugi, K | 1 |
| Hirai, H | 1 |
| Moriguchi, M | 2 |
| Ikeda, K | 1 |
| Nagai, S | 1 |
| Takeishi, Y | 1 |
| Kubota, I | 1 |
| Matsushita, K | 2 |
| Ishikawa, T | 2 |
| Sumita, S | 2 |
| Kobayashi, T | 2 |
| Matsumoto, K | 2 |
| Yamakawa, Y | 2 |
| Ohkusu, Y | 2 |
| Nakagawa, T | 2 |
| Nakazawa, I | 2 |
| Mochida, Y | 2 |
| Ebina, T | 2 |
| Uchino, K | 2 |
| Kimura, K | 2 |
| Umemura, S | 2 |
| Trappe, HJ | 1 |
| Brandts, B | 1 |
| Weismueller, P | 1 |
| Kumagai, K | 7 |
| Tojo, H | 3 |
| Noguchi, H | 3 |
| Yasuda, T | 3 |
| Ogawa, M | 3 |
| Nakashima, H | 4 |
| Zhang, B | 2 |
| Saku, K | 4 |
| Horita, Y | 1 |
| Kanaya, H | 1 |
| Uno, Y | 1 |
| Yamazaki, T | 1 |
| Kaku, B | 1 |
| Funada, A | 1 |
| Kitajima, S | 1 |
| Matsumura, M | 1 |
| Satoh, T | 1 |
| Honsho, S | 1 |
| Hashimoto, K | 1 |
| Okishige, K | 3 |
| Yamamoto, N | 1 |
| Otomo, K | 1 |
| Azegami, K | 2 |
| Isobe, M | 1 |
| Miura, S | 1 |
| Sugiura, H | 1 |
| Chinushi, M | 2 |
| Komura, S | 1 |
| Hirono, T | 1 |
| Aizawa, Y | 2 |
| Ogawa, R | 1 |
| Kishi, R | 1 |
| Mihara, K | 1 |
| Takahashi, H | 1 |
| Takagi, A | 1 |
| Matsumoto, N | 2 |
| Masuhara, K | 1 |
| Miyake, F | 1 |
| Kobayashi, S | 1 |
| Echizen, H | 1 |
| Fukunami, M | 2 |
| Atarashi, H | 2 |
| Inoue, H | 4 |
| Shinohara, T | 1 |
| Takahashi, N | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Di Diego, JM | 2 |
| Zygmunt, AC | 2 |
| Hirose, M | 1 |
| Ohkubo, Y | 1 |
| Takano, M | 1 |
| Hamazaki, M | 1 |
| Sekido, T | 1 |
| Yamada, M | 1 |
| Yi, HJ | 1 |
| Kim, DW | 1 |
| Suh, JK | 1 |
| Imai, S | 1 |
| Saito, F | 1 |
| Takase, H | 1 |
| Enomoto, M | 1 |
| Aoyama, H | 1 |
| Yamaji, S | 1 |
| Yokoyama, K | 1 |
| Yagi, H | 1 |
| Kushiro, T | 1 |
| Leclercq, JF | 1 |
| Georgiopoulos, G | 1 |
| Halkidis, H | 1 |
| Attuel, P | 1 |
| Maisonblanche, P | 1 |
| Coumel, P | 1 |
| Prystowsky, EN | 1 |
| Hart, NJ | 1 |
| Watanabe, R | 1 |
| Fujiwara, H | 1 |
| Soma, T | 1 |
| Orning, OM | 1 |
| Roden, DM | 1 |
| Duff, HJ | 1 |
| Primm, RK | 1 |
| Kronenberg, MW | 1 |
| Woosley, RL | 1 |
| Scheinman, MM | 1 |
| Hindman, MC | 1 |
| Wagner, GS | 1 |
| Chia, BL | 1 |
| Akhtar, M | 1 |
| Gilbert, CJ | 1 |
| Shenasa, M | 1 |
| Inoue, M | 3 |
| Inoue, D | 3 |
| Ishibashi, K | 3 |
| Sakai, R | 3 |
| Asayama, J | 3 |
| Fagbemi, SO | 1 |
| Chi, L | 1 |
| Lucchesi, BR | 1 |
| Omori, I | 2 |
| Yamahara, Y | 2 |
| Johnson, RG | 1 |
| Goldberger, AL | 1 |
| Thurer, RL | 1 |
| Schwartz, M | 1 |
| Sirois, C | 1 |
| Weintraub, RM | 1 |
| Scheufler, E | 1 |
| Mozes, A | 1 |
| Guttmann, I | 1 |
| Wilffert, B | 1 |
| Hiejima, K | 1 |
| Hayakawa, H | 1 |
| Raev, D | 1 |
| Leonidov, NB | 1 |
| Galenko-Iaroshevskiĭ, PA | 3 |
| Sheĭkh-Zade, IuR | 2 |
| Cherednik, IL | 2 |
| Fitilev, SB | 1 |
| Galygo, DS | 1 |
| Khankoeva, AI | 2 |
| Hayashi, H | 2 |
| Tani, M | 1 |
| Usui, M | 2 |
| Kryzhanovskiĭ, SA | 1 |
| Uvarov, AV | 1 |
| Turovaia, AIu | 1 |
| Popov, PB | 1 |
| Matsuo, K | 1 |
| Annoura, M | 1 |
| Ideishi, M | 1 |
| Arakawa, K | 1 |
| Shepard, RK | 1 |
| Natale, A | 1 |
| Stambler, BS | 1 |
| Wood, MA | 1 |
| Gilligan, DM | 1 |
| Ellenbogen, KA | 1 |
| Tabuchi, T | 1 |
| Tsuchiya, T | 1 |
| Tsunoda, R | 1 |
| Matsunaga, T | 1 |
| Tayama, S | 1 |
| Yasue, H | 1 |
| Kanki, H | 3 |
| Mitamura, H | 3 |
| Takatsuki, S | 2 |
| Sueyoshi, K | 1 |
| Shinagawa, K | 3 |
| Sato, T | 3 |
| Ogawa, S | 3 |
| Yamada, T | 1 |
| Shimonagata, T | 1 |
| Sanada, S | 1 |
| Ogita, H | 1 |
| Asano, Y | 1 |
| Hori, M | 1 |
| Hoki, N | 1 |
| Nagasawa, H | 1 |
| Mizumaki, K | 1 |
| Ozeki, S | 1 |
| Utsunomiya, T | 1 |
| Matsuo, S | 1 |
| Yano, K | 1 |
| Ohe, T | 1 |
| Takeshita, A | 2 |
| Tükek, T | 1 |
| Akkaya, V | 1 |
| Demirel, S | 1 |
| Sözen, AB | 1 |
| Kudat, H | 1 |
| Atilgan, D | 1 |
| Ozcan, M | 1 |
| Güven, O | 1 |
| Korkut, F | 1 |
| Kitano, Y | 1 |
| Marrouche, NF | 1 |
| Reddy, RK | 1 |
| Wittkowsky, AK | 1 |
| Bardy, GH | 1 |
| Nishizaki, M | 1 |
| Igawa, M | 1 |
| Yamawaki, N | 1 |
| Aonuma, K | 1 |
| Toeda, T | 1 |
| Susa, R | 1 |
| Saigawa, T | 1 |
| Abe, T | 1 |
| Yamaguchi, Y | 1 |
| Fuse, K | 1 |
| Murooka, H | 1 |
| Numata, T | 2 |
| Abe, H | 3 |
| Nagatomo, T | 2 |
| Kohshi, K | 2 |
| Nakashima, Y | 3 |
| Yasuda, M | 1 |
| Nakazato, Y | 1 |
| Yamashita, H | 1 |
| Sekita, G | 1 |
| Kawano, Y | 1 |
| Mineda, Y | 1 |
| Nakazato, K | 1 |
| Tokano, T | 1 |
| Sumiyoshi, M | 1 |
| Nakata, Y | 1 |
| Hiraki, T | 1 |
| Oginosawa, Y | 1 |
| Ikeda, H | 1 |
| Imaizumi, T | 1 |
| Conway, DS | 1 |
| Lip, GY | 1 |
| Nakamura, S | 1 |
| Tomita, H | 1 |
| Yomogida, K | 1 |
| Kurita, Y | 1 |
| Miyoshi, S | 1 |
| Hara, M | 1 |
| Chinushi, Y | 1 |
| Toida, T | 1 |
| Puletti, M | 1 |
| Curione, M | 1 |
| Sumarokov, AV | 1 |
| Mikhailov, AA | 1 |
| Roos, JC | 1 |
| Dunning, AJ | 1 |
| Klein, W | 1 |
| Hilwig, RW | 1 |
| Schley, G | 1 |
| Beckmann, R | 1 |
| Hengstebeck, W | 1 |
| Csapo, G | 1 |
| Forester, D | 1 |
| Rusconi, L | 1 |
| Sermasi, S | 1 |
| Marzaloni, M | 1 |
| Rossi, F | 1 |
| Johnson, RW | 1 |
| Keenan, TH | 1 |
| Kosh, JW | 1 |
| Sowell, JW | 1 |
| Sinatra, ST | 1 |
| Jeresaty, RM | 1 |
| Körber, H | 1 |
| Frank, HH | 1 |
| Timm, T | 1 |
| Danahy, DT | 1 |
| Aronow, WS | 1 |
| Titov, VN | 1 |
| Shargorodskiĭ, BM | 1 |
| Bracchetti, D | 2 |
| Frabetti, L | 1 |
| Mambelli, M | 1 |
| Stefanini, A | 1 |
| Magnani, B | 2 |
| Kostis, JB | 1 |
| Goodking, MJ | 1 |
| Gotzoyannis, S | 1 |
| Gerber, NH | 1 |
| Kuo, PT | 1 |
| Gill, MA | 1 |
| Miscia, VF | 1 |
| Gourley, DR | 1 |
| Josephson, ME | 1 |
| Kastor, JA | 1 |
| Kitchen, JG | 1 |
| Walsh, CA | 1 |
| Singer, LP | 1 |
| Mercando, AD | 1 |
| Furman, S | 1 |
| David, D | 1 |
| Lang, RM | 1 |
| Neumann, A | 1 |
| Borow, KM | 1 |
| Akselrod, S | 1 |
| Mor-Avi, V | 1 |
| Iwatsuki, N | 1 |
| Katoh, M | 1 |
| Ono, K | 1 |
| Amaha, K | 1 |
| Aguglia, F | 1 |
| Gnecchi, M | 1 |
| De Marzio, P | 1 |
| Bump, TE | 1 |
| Ripley, KL | 1 |
| Guezennec, A | 1 |
| Arzbaecher, R | 1 |
| Levitt, MA | 1 |
| Cummings, P | 1 |
| Martini, B | 1 |
| Bassan, L | 1 |
| Resta, M | 1 |
| Buja, GF | 1 |
| Canciani, F | 1 |
| Maddalena, F | 1 |
| Nava, A | 1 |
| Carmeliet, E | 1 |
| Janssen, PA | 1 |
| Heykants, J | 1 |
| Niemegeers, CJ | 1 |
| Remeysen, P | 1 |
| Van De Water, A | 1 |
| Van Gerven, W | 1 |
| Wauquier, A | 1 |
| Xhonneux, R | 1 |
| Doshchitsin, VL | 1 |
| Schollmeyer, P | 2 |
| Schmidt, J | 1 |
| Máté, K | 1 |
| Hardewig, A | 1 |
| Diedrich, R | 1 |
| Mathey, D | 1 |
| Bleifeld, W | 1 |
| Effert, S | 1 |
| Rios, JC | 1 |
| Dziok, CA | 1 |
| Ali, NA | 1 |
| Kaufmann, G | 1 |
| Glezer, GA | 1 |
| Megrelishvili, RI | 1 |
| Moskalenko, NP | 1 |
| Vaĭnbaum, IaS | 1 |
| Levichev, VI | 1 |
| Kühn, P | 1 |
| Koller, H | 1 |
| Kohn, P | 1 |
| Holzhey, P | 1 |
| Hartl, O | 1 |
| Clodi, PH | 1 |
| Zamfir, C | 1 |
| Turcu, E | 1 |
| Gavrilesco, S | 1 |
| Streian, C | 1 |
| Constantinesco, L | 1 |
| Chatillon, J | 1 |
| Robinson, SJ | 1 |
| Covino, BG | 1 |
| D'Amato, HE | 1 |
| Flensted-Jensen, E | 1 |
| Sandoe, E | 1 |
| Gattenlöhner, W | 1 |
| Enenkel, W | 1 |
| Polzer, K | 1 |
| Raper, C | 1 |
| Jowett, A | 1 |
| Binetti, G | 1 |
| D'Osualdo, F | 1 |
| Ewy, GA | 1 |
| Marcus, FI | 1 |
| Fillmore, SJ | 1 |
| Matthews, NP | 1 |
| Kaplinsky, E | 1 |
| Yahini, JH | 1 |
| Barzilai, J | 1 |
| Neufeld, HN | 1 |
| Preston, TA | 1 |
| Yates, JD | 1 |
| Brymer, JF | 1 |
| Nedostup, AV | 1 |
| Sarkas, A | 1 |
| Sideris, DA | 1 |
| Valianos, G | 1 |
| Alekseev, GK | 1 |
| Martynov, IV | 1 |
| Tikhonov, AA | 1 |
| Zhibkov, IuE | 1 |
| Bakulin, VD | 1 |
| Gianelly, RE | 1 |
| Harrison, DC | 1 |
| Sloman, G | 1 |
| Damato, AN | 1 |
| Lau, SH | 1 |
| Lemberg, L | 1 |
| Castellanos, A | 1 |
| Arcebal, AG | 1 |
| Iyengar, RN | 1 |
| Mulcahy, R | 1 |
| Marriott, HJ | 1 |
| Lyngborg, K | 1 |
| Jacobsen, JG | 1 |
| Baum, T | 1 |
| Eckfeld, DK | 1 |
| Shropshire, AT | 1 |
| Rowles, G | 1 |
| Varner, LL | 1 |
| Bender, F | 1 |
| Schmidt, E | 1 |
| Gradaus, D | 1 |
| Reintoft, M | 1 |
| Esser, H | 1 |
| Fricke, G | 1 |
| Kleiger, RE | 1 |
| Miller, DS | 1 |
| Blount, AW | 1 |
| Churcher, A | 1 |
| Grossman, JI | 1 |
| Lubow, LA | 1 |
| Frieden, J | 1 |
| Rubin, IL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pre-Operative Stellate Ganglion to Prevent Post-Operative Atrial Fibrillation[NCT05656170] | 0 participants (Actual) | Interventional | 2023-10-01 | Withdrawn (stopped due to Unable to begin study) | |||
| The Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Video-assisted Thoracoscopic Surgeries: A Randomized Controlled Trial[NCT05753644] | 480 participants (Anticipated) | Interventional | 2023-03-27 | Recruiting | |||
| Ultrasound Guided Transversus Abdominis Plane Block Versus Erector Spina Plane Block in Pediatric Lower Abdominal Surgery[NCT04095325] | 100 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | |||
| Effect of Ultrasonography Guided Transversus Abdominis Plane Block to Intraoperative Anesthesia in Children: Randomized Controlled Study[NCT02990975] | 60 participants (Anticipated) | Interventional | 2016-12-31 | Active, not recruiting | |||
| Ultrasonography Guided Ilioinguinal /Iliohypogastric Block Versus Transversus Abdominis Plane Block in Intraoperative Anesthesia in Children - Randomized Controlled Study[NCT02991053] | 100 participants (Anticipated) | Interventional | 2016-12-31 | Active, not recruiting | |||
| Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide[NCT03005366] | Phase 4 | 50 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| A Single Site, Interventional, Comparative Study to Evaluate the Safety and Efficacy of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences[NCT03162120] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to new study type, it will be re-organiZed as an Investigator Initiated Study (IIS)) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for lidocaine and Auricular Fibrillation
| Article | Year |
|---|---|
Arrhythmias in the intensive care patient.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 2003 |
Pilsicainide for atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Combined Modality Therapy; | 2006 |
Pharmacologic therapy of tachyarrhythmias in patients with Wolff-Parkinson-White syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Ajmaline; Amiodarone; Anilides; Aprindine; Atr | 1983 |
Arrhythmias during myocardial infarction: Mechanisms, significance, and therapy.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; Bradycardia; Heart Block; Humans; | 1980 |
Ventricular pacing failure after a single oral dose of pilsicainide in a patient with a permanent pacemaker and paroxysmal atrial fibrillation.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Combined Modality Therapy; | 2000 |
New antiarrhythmic agents for atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Hydantoins; Imidazoles; Imidazolidines | 2001 |
Cardiac arrhythmias in the dog: detection and treatment.
Topics: Animals; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardia; Cardiac Complexe | 1976 |
The treatment of common cardiac arrhythmias.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillation; Atropine | 1976 |
[Cardiac arrhythmias. I. Pathogenesis and clinical significance].
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillat | 1971 |
Digitalis-induced arrhythmias: recognition and management.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atropine; Cardiac Complexes, Premature; Digitalis Glycosi | 1970 |
[Anti-arrhythmia agents].
Topics: Action Potentials; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atri | 1974 |
Treatment of cardiac arrhythmias.
Topics: Adams-Stokes Syndrome; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; | 1964 |
Current status of antiarrhythmic drug therapy.
Topics: Anesthetics, Local; Anti-Arrhythmia Agents; Anticonvulsants; Antimalarials; Arrhythmias, Cardiac; At | 1968 |
[Clinical aspects and therapy of acute coronary occlusion].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiomegaly; Coronary Care Units; Corona | 1972 |
Digitalis intoxication--diagnosis, management and prevention.
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; Digitalis Glycosides; Digoxi | 1974 |
Drugs used in the treatment of cardiac arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Autonomic Nervous System | 1969 |
Changing concepts in the care of patients with acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Blood Gas Analysis; Bundle-Branch Block; Cardiac Output; | 1969 |
Clinical value of the electrogram of the conduction system.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Atropine; Bundle-Branch Block; Cardiac Catheterization; C | 1970 |
The treatment of arrhythmias following acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atropine; Bradycardia; Coronary Care Units; Digitalis Gly | 1971 |
Intensive coronary care: current status and future prospects.
Topics: Analgesics; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Atropine; Bradycardia; Coro | 1971 |
Management of cardiac dysrhythmias complicating acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atropine; Bradycardia; Bretylium Compound | 1968 |
17 trials available for lidocaine and Auricular Fibrillation
| Article | Year |
|---|---|
Acute effects of unilateral temporary stellate ganglion block on human atrial electrophysiological properties and atrial fibrillation inducibility.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Autonomic Nerve Block; Female; Heart Atria; Heart Condu | 2016 |
Acute effects of unilateral temporary stellate ganglion block on human atrial electrophysiological properties and atrial fibrillation inducibility.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Autonomic Nerve Block; Female; Heart Atria; Heart Condu | 2016 |
Acute effects of unilateral temporary stellate ganglion block on human atrial electrophysiological properties and atrial fibrillation inducibility.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Autonomic Nerve Block; Female; Heart Atria; Heart Condu | 2016 |
Acute effects of unilateral temporary stellate ganglion block on human atrial electrophysiological properties and atrial fibrillation inducibility.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Autonomic Nerve Block; Female; Heart Atria; Heart Condu | 2016 |
A randomized study on the efficacy of intravenous cibenzoline and pilsicainide administered prior to electrical cardioversion in patients with lone paroxysmal and persistent atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Electric Countershock; | 2009 |
Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the surface ECG.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Cross-Over Studies; Electrocardiography | 2009 |
Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Electrocardiography; Female; Flecainide; Huma | 2003 |
Low-dose flecainide infusion followed by oral pilsicainide is highly effective and safe for paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Therapy, Combination; Female; Flecainide; Humans; | 2003 |
Hybrid therapy with pilsicainide and pulmonary vein isolation for atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Electrophysiology; Female; Heart Atr | 2005 |
Population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bundle-Branch Block; | 2006 |
Pharmacological conversion of persistent atrial fibrillation into sinus rhythm with oral pilsicainide: pilsicainide suppression trial for persistent atrial fibrillation II.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cont | 2006 |
Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy.
Topics: Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Disease-F | 2006 |
Use of bepridil in combination with Ic antiarrhythmic agent in converting persistent atrial fibrillation to sinus rhythm.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Natriuretic Factor; Bepridil; Drug | 2008 |
Lidocaine prophylaxis in coronary revascularization patients: a randomized, prospective trial.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Output, Low; Coronary Artery Bypa | 1993 |
Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Double-Blind Method; | 1996 |
Mechanism of antiarrhythmic effects of class Ic drugs in paroxysmal atrial fibrillation in man.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Arti | 1998 |
High-dose bolus lidocaine for chemical cardioversion of atrial fibrillation: a prospective, randomized, double-blind crossover trial.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Dose-Response Relationship, D | 2000 |
Pilsicainide for conversion and maintenance of sinus rhythm in chronic atrial fibrillation: a placebo-controlled, multicenter study.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chronic Disease; Drug Admin | 2000 |
Single oral administration of pilsicainide versus infusion of disopyramide for termination of paroxysmal atrial fibrillation: a multicenter trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; C | 2000 |
Clinical value of the electrogram of the conduction system.
Topics: Aged; Atrial Fibrillation; Atrial Flutter; Atropine; Bundle-Branch Block; Cardiac Catheterization; C | 1970 |
133 other studies available for lidocaine and Auricular Fibrillation
| Article | Year |
|---|---|
New antiarrhythmic agents. 2. Amide alkyl alpha-amino xylidides.
Topics: Aniline Compounds; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical Phenomena; Chemist | 1979 |
New antiarrhythmic agents. 3. Primary beta-amino anilides.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chloroform; Coronary Vessels; Dogs; | 1979 |
Synthesis and biological studies of novel 2-aminoalkylethers as potential antiarrhythmic agents for the conversion of atrial fibrillation.
Topics: Administration, Oral; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Biological Availability; | 2007 |
Rhythm disturbances associated with lidocaine administration in four dogs with supraventricular tachyarrhythmias.
Topics: Animals; Atrial Fibrillation; Dog Diseases; Dogs; Electric Countershock; Lidocaine; Tachycardia; Ven | 2022 |
Involvement of the persistent Na
Topics: Action Potentials; Animals; Atrial Fibrillation; Cells, Cultured; Diastole; Guinea Pigs; Lidocaine; | 2019 |
Pilsicainide Intoxication with Neuropsychiatric Symptoms Treated with Continuous Hemodiafiltration.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hallucinations; Hemodiafiltration; Humans | 2020 |
Conversion of atrial dissociation with lidocaine in a dog.
Topics: Abdomen; Animals; Atrial Fibrillation; Dog Diseases; Dogs; Electrocardiography; Foreign Bodies; Hear | 2017 |
Can local infiltration of lidocaine reduce the postoperative atrial fibrillation rate in patients undergoing lobectomy for lung cancer?
Topics: Aged; Anesthesia, Local; Anesthetics, Local; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Fe | 2020 |
Effect of Lidocaine Injection of Ganglionated Plexi in a Canine Model and Patients With Persistent and Long-Standing Persistent Atrial Fibrillation.
Topics: Action Potentials; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; At | 2019 |
Anesthetizing the Fibrillating Heart.
Topics: Animals; Atrial Fibrillation; Dogs; Heart; Heart Rate; Humans; Lidocaine | 2019 |
Prophylactic amiodarone and lidocaine improve survival in an ovine model of large size myocardial infarction.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disease Mode | 2013 |
Electrophysiological effects of an anti-influenza drug oseltamivir on the guinea-pig atrium: comparison with those of pilsicainide.
Topics: Animals; Anti-Arrhythmia Agents; Antiviral Agents; Atrial Fibrillation; Atrial Function; Atrial Func | 2013 |
Altered responses to vasopressors of a patient medicated with carvedilol, pilsicainide and enalapril.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atria | 2014 |
Idiopathic ventricular fibrillation associated with early repolarization which was unmasked by a sodium channel blocker after catheter ablation of atrial fibrillation.
Topics: Atrial Fibrillation; Catheter Ablation; Electrocardiography; Female; Follow-Up Studies; Humans; Inje | 2014 |
Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Delayed Rectifier Potassium | 2015 |
Atrial Fibrillation Attributed to Local Anesthesia With Epinephrine for Mohs Micrographic Surgery.
Topics: Aged, 80 and over; Anesthesia, Local; Anesthetics, Local; Atrial Fibrillation; Carcinoma, Squamous C | 2016 |
A Novel SCN5A Mutation Associated with Drug Induced Brugada Type ECG.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Base Sequence; Brugada Syndrome; | 2016 |
Combination of femoral and genitofemoral nerve blocks is effective for endovascular aneurysm repair.
Topics: Aged; Amides; Anesthesia, General; Anesthetics, Local; Aortic Aneurysm, Abdominal; Atrial Fibrillati | 2017 |
Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Body Surface Potential Mapp | 2008 |
Effect of pilsicainide on dominant frequency in the right and left atria and pulmonary veins during atrial fibrillation: association with its atrial fibrillation terminating effect.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Echocardiography; Electrophysi | 2009 |
Simultaneous assessment of pharmacokinetics of pilsicainide transdermal patch and its electropharmacological effects on atria of chronic atrioventricular block dogs.
Topics: Administration, Cutaneous; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Bl | 2009 |
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy.
Topics: Action Potentials; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atri | 2010 |
How the heart can fibrillate: when diversity is a disadvantage.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Chlor | 2010 |
When palpitations worsen.
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Diagnosis, Differential; Electric Countershock; | 2010 |
Convulsions after normal dose of lidocaine: a probable drug interaction.
Topics: Adrenergic alpha-Agonists; Aged; Anesthetics, Local; Anti-Arrhythmia Agents; Atrial Fibrillation; Br | 2012 |
Pharmacologic atrial defibrillation by drug delivery into the temporarily occluded coronary sinus. A canine study.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Balloon Occlusion; Cardiac Pacing, Artificial; | 2012 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Hemiarthroplasty performed under transversus abdominis plane block in a patient with severe cardiorespiratory disease.
Topics: Abdomen; Aged; Anesthetics, Combined; Anesthetics, Local; Atrial Fibrillation; Bupivacaine; Fatal Ou | 2013 |
Atrial fibrillation threshold predicted long-term efficacy of pharmacological treatment of patients without structural heart disease.
Topics: Aged; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Disopyramide; Electrophysiologic Techn | 2002 |
Evaluation of the effect of bepridil on paroxysmal atrial fibrillation: relationship between efficacy and the f-f interval in surface ECG recordings.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Bepridil; Calcium Channel Blockers; Electrocardio | 2003 |
Widening of the excitable gap and enlargement of the core of reentry during atrial fibrillation with a pure sodium channel blocker in canine atria.
Topics: Acetylcholine; Animals; Atrial Fibrillation; Body Surface Potential Mapping; Dogs; Dose-Response Rel | 2003 |
Effect of pilsicainide on atrial electrophysiologic properties in the canine rapid atrial stimulation model.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; D | 2003 |
[Factors for successful conversion of atrial fibrillation using intravenous injection of pilsicainide hydrochloride].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Injections, | 2003 |
[Brugada syndrome associated with ventricular fibrillation induced by administration of pilsicainide: a case report].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Electrophysiology; Humans; Lidocai | 2003 |
Effects of the NA+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation.
Topics: Atrial Fibrillation; Electrophysiologic Techniques, Cardiac; Female; Humans; Infusions, Intravenous; | 2004 |
A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Creatinine; Drug Overdose; Ele | 2004 |
A simple in vivo atrial fibrillation model of rat induced by transesophageal atrial burst pacing.
Topics: Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Disease Models, Animal; Electrocardiograph | 2005 |
Long-term efficacy of hybrid pharmacologic and ablation therapy in patients with pilsicainide-induced atrial flutter.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Cathe | 2005 |
Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cholinergic Antagonists; Disopyramide; Dogs; E | 2005 |
Pilsicainide-induced ventricular tachycardia originating from right ventricular outflow tract.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Humans; Lidocaine; Middle Aged; Tachycardia, Ve | 2007 |
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic A | 2007 |
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic A | 2007 |
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic A | 2007 |
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiotonic A | 2007 |
Mechanisms of the preventive effect of pilsicainide on atrial fibrillation originating from the pulmonary vein.
Topics: Acetylcholine; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Electr | 2007 |
Hypotensive shock during anesthesia for endovascular embolization.
Topics: Adrenergic Agents; Adrenergic Agonists; Aged; Anaphylaxis; Anesthesia; Anti-Arrhythmia Agents; Atria | 2008 |
Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.
Topics: Acetanilides; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Electrophysiol | 2008 |
[Effects of anti-arrhythmia agents on heart rate. Significance and importance].
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 1981 |
Therapeutic considerations in the treatment of common cardiac arrhythmias.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardiac Complexes | 1981 |
Pressure gradient and blood flow in human arm veins--a proposed explanation of the pumping mechanism.
Topics: Adult; Aged; Arm; Atrial Fibrillation; Blood Flow Velocity; Central Venous Pressure; Dextrans; Femal | 1984 |
The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular Node; | 1984 |
Control of ventricular preexcitation and associated arrhythmias by encainide.
Topics: Anilides; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Encainide; Female; Heart V | 1981 |
Treatment of cardiac arrhythmias in patients with acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Bundle-Branch Block; Heart Block; Hemodynamics; Humans; I | 1983 |
Digitalis-induced cardiac arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atropine; Cardiac Pacing, Artificial; Digitalis Gly | 1981 |
Effect of lidocaine on atrioventricular response via the accessory pathway in patients with Wolff-Parkinson-White syndrome.
Topics: Adult; Atrial Fibrillation; Atrioventricular Node; Electrocardiography; Electrophysiology; Female; H | 1981 |
Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs.
Topics: Acetylcholine; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Disopyramide; | 1994 |
Antifibrillatory and profibrillatory actions of selected class I antiarrhythmic agents.
Topics: Adenosine Triphosphate; Animals; Anti-Arrhythmia Agents; Aprindine; Atrial Fibrillation; Blood Gas A | 1993 |
[Effect of pilsicainide hydrochloride on atrial fibrillation threshold].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Lidoc | 1993 |
Effects of pilsicainide on the atrial fibrillation threshold in guinea pig atria. A comparative study with disopyramide, lidocaine and flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrophysiology; Female; Fleca | 1993 |
R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzothiazoles; Calcium; Calcium Channel Block | 1995 |
Carotid sinus pressure: a new application of an old maneuver. A preliminary report.
Topics: Adenosine; Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Pressure; Carotid Sinus; | 1996 |
[Comparative evaluation of the anti-arrhythmia effect of KLN-93, dicaine, and lidocaine during neurogenic atrial fibrillation].
Topics: 4-Aminobenzoic Acid; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cats; | 1997 |
Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Dogs; Electric Stimulation; F | 1998 |
[Cardioprotective effects of the cyclic derivative of gamma-aminobutyric acid T3-146 during reperfusion].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cats; Electr | 1997 |
Physiology of the escape rhythm after radiofrequency atrioventricular junctional ablation.
Topics: Adenosine; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrioventricular Node; Atropine; Bundl | 1998 |
Effects of pilsicainide and propafenone on vagally induced atrial fibrillation: role of suppressant effect in conductivity.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Output; Dogs; Electric Conductivity; E | 1998 |
Postrepolarization refractoriness as a potential anti-atrial fibrillation mechanism of pilsicainide, a pure sodium channel blocker with slow recovery kinetics.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Dogs; Drug Evaluation, Prec | 1998 |
Dispersion of signal-averaged P wave duration on precordial body surface in patients with paroxysmal atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 1999 |
ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Flecainide; Follow-Up Studies; Hea | 1999 |
Pilsicainide intoxication in a patient with dehydration.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Dehydration; Electrocardiograp | 1999 |
[Significance of neurotropic component in therapeutic effect of the anti-arrhythmia agents].
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cats; Lidocaine; Procainamide; Vagus Nerve | 1999 |
Effect of pilsicainide, a pure sodium channel blocker, on spiral waves during atrial fibrillation: theoretical analysis by numerical simulation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Computer Simulation; Culture Techniques; Electrocardiog | 1999 |
Determination of refractory periods and conduction velocity during atrial fibrillation using atrial capture in dogs: direct assessment of the wavelength and its modulation by a sodium channel blocker, pilsicainide.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; Electrocardi | 2000 |
Effect of Valsalva maneuver on surface electrocardiographic P-wave dispersion in paroxysmal atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Electrocardiography; Female; Heart Rate; Humans; Lidoca | 2000 |
Transient appearance of antegrade conduction via an AV accessory pathway caused by atrial fibrillation in a patient with intermittent Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Electrocardiography | 2000 |
A case of sinus pause due to the proarrhythmia of pilsicainide.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Consciousness Disorders; El | 2000 |
Effect of a single oral dose of pilsicainide on pacing thresholds in pacemaker patients with and without paroxysmal atrial fibrillation.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardi | 2000 |
ST segment elevation in the right precordial leads following administration of class Ic antiarrhythmic drugs.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Female | 2001 |
[Efficacy of pilsicainide for the long-term prevention of paroxysmal atrial fibrillation: analysis based on the time of onset].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; Humans; Hypertensi | 2001 |
Effects of ionic remodeling on cardiac antiarrhythmic drug actions.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Down-Regulation; Electric C | 2001 |
Electropharmacologic effects of pilsicainide, a pure sodium channel blocker, on the remodeled atrium subjected to chronic rapid pacing.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Cardiac Pacing, Artificial; C | 2001 |
Class I antiarrhythmic drug and coronary vasospasm-induced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina.
Topics: Acetylcholine; Angina Pectoris, Variant; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibril | 2002 |
[Drug therapy of pre-excitation syndromes].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrilla | 1977 |
[Certain practical problems of recognition and treatment of cardiac rhythm disorders].
Topics: Ajmaline; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Cardiac Glycoside | 1975 |
Effects of lidocaine on impulse formation and conduction defects in man.
Topics: Adult; Aged; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Atriovent | 1975 |
[Drug therapy of tachycardial heart-rhythm disorders].
Topics: Adrenergic beta-Antagonists; Ajmaline; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; | 1976 |
[The treatment of acute cardiac dysrhythmias with atenolol (Tenormin) particularly after myocardial infarction (author's transl)].
Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrial Flutter; Car | 1978 |
Paroxysmal nonreentrant tachycardias due to simultaneous conduction in dual atrioventricular nodal pathways.
Topics: Adult; Ajmaline; Atrial Fibrillation; Atrioventricular Node; Atropine; Bundle of His; Cardiac Pacing | 1979 |
Treatment of arrhythmias in the Wolff-Parkinson-White syndrome.
Topics: Administration, Oral; Atrial Fibrillation; Disopyramide; Humans; Injections, Intravenous; Lidocaine; | 1979 |
[Lidocaine administration in a patient with Wolff-Parkinson-White syndrome and atrial fibrillation (author's transl)].
Topics: Atrial Fibrillation; Female; Humans; Lidocaine; Middle Aged; Wolff-Parkinson-White Syndrome | 1979 |
Synthesis of substituted 2-aminopyrrole analogs of lidocaine II.
Topics: Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Chemical Phenomena; Chemis | 1979 |
Enhanced atrioventricular conduction atrial fibrillation after lidocaine administration.
Topics: Aged; Aminophylline; Atrial Fibrillation; Atrioventricular Node; Heart Conduction System; Heart Rate | 1977 |
[Problems in the medicamentous defibrillation of the heart].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Drug Therapy, Combination; Electroc | 1977 |
Lidocaine-induced cardiac rate changes in atrial fibrillation and atrial flutter.
Topics: Adult; Aged; Atrial Fibrillation; Atrial Flutter; Digoxin; Drug Interactions; Electrocardiography; H | 1978 |
[Parallel study of the fibrillation and excitation thresholds in the cardiac ventricles in experimental animals].
Topics: Action Potentials; Animals; Atrial Fibrillation; Cats; Depression, Chemical; Dogs; Electric Stimulat | 1977 |
[Comparative study of the effects of various antiarrhythmic drugs on the frequency of ventricular response during established atrial fibrillation].
Topics: Ajmaline; Anti-Arrhythmia Agents; Atrial Fibrillation; Digoxin; Heart Rate; Heart Ventricles; Humans | 1977 |
Effect of lidocaine on the atrial fibrillation threshold.
Topics: Action Potentials; Animals; Atrial Fibrillation; Dogs; Heart; Lidocaine; Ventricular Fibrillation | 1977 |
Lidocaine in Wolff-Parkinson-White syndrome with atrial fibrillation.
Topics: Adolescent; Atrial Fibrillation; Electrocardiography; Hospitalization; Humans; Lidocaine; Male; Proc | 1976 |
Differentiation of sinus rhythms from supraventricular tachydysrhythmias by activation sequence and timing.
Topics: Animals; Atrial Fibrillation; Atrial Flutter; Atrial Function, Left; Atrioventricular Node; Bloodlet | 1990 |
Parasympathetically modulated antiarrhythmic action of lidocaine in atrial fibrillation.
Topics: Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Atropine; Dogs; Electric Stimulation; Electrocar | 1990 |
Antiarrhythmic effect of diltiazem during halothane anesthesia in dogs and in humans.
Topics: Adolescent; Adult; Aged; Anesthesia, Inhalation; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; | 1985 |
Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Dru | 1985 |
The effect of drugs and lead maturation on atrial electrograms during sinus rhythm and atrial fibrillation.
Topics: Algorithms; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dogs; | 1989 |
Wolff-Parkinson-White syndrome with atrial fibrillation.
Topics: Atrial Fibrillation; Humans; Lidocaine; Wolff-Parkinson-White Syndrome | 1988 |
Lidocaine unpredictable for patients with Wolff-Parkinson-White syndrome in atrial fibrillation.
Topics: Atrial Fibrillation; Humans; Lidocaine; Wolff-Parkinson-White Syndrome | 1988 |
[Restoration of sinus rhythm by lidocaine in a case of atrial fibrillation with high ventricular response in a patient with Wolf-Parkinson-White syndrome].
Topics: Adult; Arrhythmia, Sinus; Atrial Fibrillation; Electrocardiography; Heart Ventricles; Humans; Lidoca | 1988 |
Electrophysiologic, antiarrhythmic and hemodynamic effects of transcainide.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calci | 1987 |
[Use of lidocaine to treat patients with cardiac rhythm disturbances].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Blood Pressure; Cardiac Comp | 1970 |
[Cardiac rhythm disorders. 2. Therapy].
Topics: Adrenergic alpha-Antagonists; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial F | 1971 |
Idioventricular tachycardia elicited by the combined administration of trasicor and lidocain.
Topics: Adrenergic beta-Antagonists; Aged; Allyl Compounds; Amino Alcohols; Atrial Fibrillation; Cardiac Com | 1972 |
[What is assured in the treatment of heart arrhythmia?].
Topics: Adrenergic beta-Antagonists; Ajmaline; Atrial Fibrillation; Atrial Flutter; Atropine; Bradycardia; C | 1972 |
[Oral therapy of cardiac arrhythmia using Neo-Gilurytmal (N-n-propyl-ajmalinium-hydrogentartrate)].
Topics: Administration, Oral; Adult; Aged; Ajmaline; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Comp | 1973 |
[Use of lidocaine in arrhythmias].
Topics: Administration, Oral; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pres | 1974 |
[Arrhythmias in acute myocardial infarct].
Topics: Acidosis; Acute Disease; Arrhythmias, Cardiac; Aspartic Acid; Atrial Fibrillation; Atrial Flutter; B | 1973 |
[Therapy of arrhythmias].
Topics: Ajmaline; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardia; Caffeine; Cardiac Complexes, Prema | 1973 |
[Treatment of paroxysmal disorders of cardiac rhythm].
Topics: Acetanilides; Adrenergic beta-Antagonists; Ajmaline; Amino Alcohols; Arrhythmias, Cardiac; Atrial Fi | 1972 |
[Associated ventricular tachycardia and auricular fibrillation after anticholera vaccination].
Topics: Acetanilides; Adrenergic beta-Antagonists; Amino Alcohols; Atrial Fibrillation; Cholera Vaccines; El | 1973 |
[The treatment of cardiac arrhythmias: complexity and schematization].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atri | 1973 |
Lidocaine as an antiarrhythmic Experience in 68 patients.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Card | 1969 |
[Arrhythmias in myocardial infarct].
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Heart Block; Heart Ma | 1970 |
Anti-fibrillary and anti-adrenaline activity of beta-receptor blocking drugs.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cats; Epinephrine; Ethanolamines; Gu | 1967 |
Treatment of cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Digitalis; Digoxin; Electric Countershock | 1974 |
[Contraindications to the use of digitalis in atrial fibrillation in the course of Wolff-Parkinson-White syndrome].
Topics: Aged; Atrial Fibrillation; Digoxin; Electrocardiography; Hemodynamics; Humans; Lidocaine; Male; Prac | 1974 |
Quinidine syncope; report of a case successfully treated with lidocaine.
Topics: Adult; Atrial Fibrillation; Electrocardiography; Female; Humans; Lidocaine; Quinidine; Syncope; Tach | 1972 |
Three therapeutic approaches in tachycardia.
Topics: Atrial Fibrillation; Atrial Flutter; Digitalis Glycosides; Electric Countershock; Heart Conduction S | 1973 |
[Certain problems of emergency therapy of the disorders of cardiac rhythm].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Glycosides; Humans; Lidocaine; Myocardial Infarct | 1973 |
Multiform Wolff-Parkinson-White syndrome.
Topics: Adolescent; Atrial Fibrillation; Electrocardiography; Heart Conduction System; Humans; Lidocaine; Ma | 1974 |
[Evaluation of some methods of treating cardiac arrhythmias].
Topics: Adams-Stokes Syndrome; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillatio | 1974 |
Intractable paroxysmal tachycardia in thyrotoxicosis simulating myocardial infarction.
Topics: Angina Pectoris; Atrial Fibrillation; Bradycardia; Cardiac Catheterization; Diagnosis, Differential; | 1972 |
Observations on models used for the evaluation of antiarrhythmic drugs.
Topics: Alkaloids; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutte | 1971 |
[Drug therapy of arrhythmias].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Bradycardia; Female; Human | 1969 |
[Lidocaine for arrhythmias. A case of ventricular flutter-fibrillation presumably provoked by lidocaine].
Topics: Aged; Atrial Fibrillation; Electric Countershock; Female; Humans; Injections, Intravenous; Lidocaine | 1970 |
[Therapy of the most important cardiac arrhythmias].
Topics: Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia; Electric Countershock; Gluca | 1970 |
Cardioversion of paroxysmal arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Digitalis; Electric Countershock; E | 1970 |
Quinidine-induced recurrent ventricular fibrillation: (quinidine syncope) treated with transvenous pacemaker.
Topics: Adult; Atrial Fibrillation; Atropine; Blood Cell Count; Chlorpromazine; Coumarins; Creatine Kinase; | 1971 |
Lignocaine in cardiac arrhythmias.
Topics: Aged; Atrial Fibrillation; Female; Humans; Injections, Intravenous; Lidocaine | 1968 |
Lidocaine in cardiac arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Electrocardiography; Heart Ventricles; Human | 1968 |